A comparative study of nebulized 3% hypertonic saline and normal saline in the management of respiratory syncytial virus-positive acute bronchiolitis in young infants

Mahmuda Khanom; Probir Kumar Sarkar; K. M. Ishtiaque Sayeed; M. Mahbub Al Amin; Fahmida Ferdous; Ayesha Siddika Tonny; Farhana Bhuiyan

doi:10.18203/2349-3291.ijcp20252212

Authors

Mahmuda Khanom Department of Pediatrics, Hope Maternal and Child Hospital, Cox’s Bazar, Bangladesh
Probir Kumar Sarkar Department of Pediatric Respiratory Medicine, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
K. M. Ishtiaque Sayeed UNICEF, Bangladesh
M. Mahbub Al Amin Department of Pediatric Cardiology, National Institute of Cardiovascular Disease (NICVD), Shere E Bangla Nagar, Dhaka
Fahmida Ferdous Department of Pediatrics, Dhaka North City Corporation COVID-19 Dedicated Hospital, Dhaka, Bangladesh
Ayesha Siddika Tonny Department of Pediatrics, Kurmitola 500 Bed General Hospital, Dhaka, Bangladesh
Farhana Bhuiyan Ministry of Labour and Employment, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2349-3291.ijcp20252212

Keywords:

Hypertonic saline, Normal saline, RSV, Bronchiolitis, Infants, MRDAI, Oxygen therapy, Hospital stay

Abstract

Background: Acute bronchiolitis due to respiratory syncytial virus (RSV) is a major cause of hospitalization in infants, yet optimal therapeutic strategies are still under evaluation. Hypertonic saline has gained interest for its potential mucolytic and anti-edematous benefits. This study aimed to evaluate the clinical efficacy of nebulized 3% hypertonic saline compared to 0.9% normal saline in managing RSV-positive acute bronchiolitis in infants up to two months old.

Methods: A double-blind, randomized controlled trial was conducted at Dhaka Shishu (Children) hospital involving 90 infants aged≤60 days with confirmed RSV-positive bronchiolitis. Participants were randomly assigned to receive either nebulized 3% hypertonic saline or 0.9% normal saline, administered three times daily until discharge. Clinical efficacy was measured using the modified respiratory distress assessment instrument (MRDAI), duration of oxygen therapy, and length of hospital stay.

Results: The hypertonic saline group showed significantly greater clinical improvement starting at 12 hours post-intervention (MRDAI: 5.20±0.19 vs. 5.98±0.23; p=0.005). These infants also required shorter oxygen therapy (10.12±1.61 vs. 11.54±1.46 hours; p=0.025) and had significantly reduced hospital stays (62.98±2.29 vs. 79.64±3.69 hours; p=0.0001).

Conclusions: Nebulized 3% hypertonic saline is more effective than normal saline in improving clinical outcomes in RSV-positive bronchiolitis in infants under two months, significantly reducing disease severity, oxygen requirement, and hospitalization duration. Incorporation into treatment protocols is strongly recommended.

Metrics

Metrics Loading ...

References

Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. J Pediat. 2017;93(1):75-83. DOI: https://doi.org/10.1016/j.jped.2017.07.003

Verma N, Lodha R, Kabra SK. Recent advances in management of bronchiolitis. Indian Pediatr. 2023;50(10):939-49. DOI: https://doi.org/10.1007/s13312-013-0265-z

Darville T. Chlamydia trachomatis infections in neonates and young children. Sem Pediat Infect Dis. 2005;16(4):235-44. DOI: https://doi.org/10.1053/j.spid.2005.06.004

Van Woensel JB, Wolfs TF, Van Aalderen WM, Brand PL, Kimpen JL. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax. 1997;52(7):634-7. DOI: https://doi.org/10.1136/thx.52.7.634

Kabir AL, Amin MR, Mollah MA, Khanam S, Mridha AA, Ahmed S, et al. Respiratory disorders in under-five children attending different hospitals of Bangladesh: A cross-sectional survey. J Respirat Med Res Treat. 2016;11(10.5171):2016-183615.

Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, et al. The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial. Europ Respirat J. 2014;44(4):913-21. DOI: https://doi.org/10.1183/09031936.00159613

Kellner JD, Scheifele D, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J. 2008;27(6):526-32. DOI: https://doi.org/10.1097/INF.0b013e3181658c5c

Flores JA, Sierro FJ, Francés G, Vázquez A, Zamarren I. The last 100,000 years in the western Mediterranean: sea surface water and frontal dynamics as revealed by coccolithophores. Marine Micropaleontol. 1997;29(3-4):351-66. DOI: https://doi.org/10.1016/S0377-8398(96)00029-1

Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 2010;157(4):630-4. DOI: https://doi.org/10.1016/j.jpeds.2010.04.074

Baron J, El-Chaar G. Hypertonic saline for the treatment of bronchiolitis in infants and young children: a critical review of the literature. J Pediatr Pharmacol Therapeut. 2016;21(1):7-26. DOI: https://doi.org/10.5863/1551-6776-21.1.7

Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, et al. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 2002;122(6):2015-20. DOI: https://doi.org/10.1378/chest.122.6.2015

Kuzik BA, Al Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediat. 2007;151(3):266-70. DOI: https://doi.org/10.1016/j.jpeds.2007.04.010

Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Therapeut. 2008;83(5):761-9. DOI: https://doi.org/10.1038/sj.clpt.6100400

Mazur NI, Caballero MT, Nunes MC. Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies. The Lancet. 2024;404(10458):1143-56. DOI: https://doi.org/10.1016/S0140-6736(24)01716-1

Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502. DOI: https://doi.org/10.1542/peds.2014-2742

Khanal A, Sharma A, Basnet S, Sharma PR, Gami FC. Nebulised hypertonic saline (3%) among children with mild to moderately severe bronchiolitis-a double blind randomized controlled trial. BMC Pediat. 2015;15:1-8. DOI: https://doi.org/10.1186/s12887-015-0434-4

Malik G, Singh A, Singh K, Pannu MS, Singh P, Banga S, Jain R. A comparative study to assess the effects of nebulised 3% hypertonic saline, 0.9% normal saline and salbutamol in management of acute bronchiolitis among Indian children. J Evolut Med Dental Sci. 2015;4(21):3662-8. DOI: https://doi.org/10.14260/jemds/2015/527

Islam MS, Mollah MA, Khanam R, Chowdhury AS, Rahman MM, Al Baqui SA, Rashid MA. Comparative efficacy of nebulized 7% hypertonic saline versus 0.9% normal saline with salbutamol in children with acute bronchiolitis. Bangladesh J Child Health. 2019;43(2):80-4. DOI: https://doi.org/10.3329/bjch.v43i2.42550

Restori KH, Srinivasa BT, Ward BJ, Fixman ED. Neonatal immunity, respiratory virus infections, and the development of asthma. Front Immunol. 2018;9:1249. DOI: https://doi.org/10.3389/fimmu.2018.01249

Kabra SK, Broor S, Lodha R, Maitreyi RS, Ghosh M, Pandey RM, Puranik M. Can we identify acute severe viral lower respiratory tract infection clinically? Indian Pediat. 2004;41(3):245-9.

Alisamir M, Mirkarimi M, Mirzaee S, Heidari S, Barouti S, Mohammadi S. Characteristics and outcomes of patients admitted to a pediatric intensive Care Unit in Southwest of Iran. Acta Medica Iranica. 2022;60(10):646-54. DOI: https://doi.org/10.18502/acta.v60i10.11558

Silver AH, Esteban-Cruciani N, Azzarone G, Douglas LC, Lee DS, Liewehr S, et al. 3% hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial. Pediatrics. 2015;136(6):1036-43. DOI: https://doi.org/10.1542/peds.2015-1037

Amara S, Dicke T. Scientific Abstract Sessions. J Allergy Clin Immunol. 2007;119(1):S316-71. DOI: https://doi.org/10.1016/S0091-6749(06)03112-5

Amin MR, Ahmmad BN, Rahman F, Hossain MM, Rashed SM. Magnitude of Pneumonia and Bronchiolitis and Their Treatment Modalities Practiced in Under Five Children Attending a Tertiary Care Hospital. J Teach Asso. 2023;36(2):163-70. DOI: https://doi.org/10.3329/taj.v36i2.72497

KB MK. Comparison of 3% saline vs normal saline as diluent for nebulisation in hospitalized young children with bronchiolitis: a randomized prospective clinical trial, Doctoral dissertation, Rajiv Gandhi University of Health Sciences, India. 2009.

Zhang L, Mendoza-Sassi RA, Wainwright CE, Aregbesola A, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syste Rev. 2023;4(4):CD006458. DOI: https://doi.org/10.1002/14651858.CD006458.pub5

Popp A, Mäki M. Changing pattern of childhood celiac disease epidemiology: contributing factors. Front Pediat. 2019;7:357. DOI: https://doi.org/10.3389/fped.2019.00357